CompletedPhase 4

Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine

United States512 participantsStarted 2020-09-15

Plain-language summary

The primary objective of this study is to evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. In the opinion of the investigator, did not offer any evidence of a therapeutic response or
✕. Was discontinued for less than 12 weeks from the date of initial screening or
✕. Was previously discontinued due to a known adverse drug reaction

Change From Baseline in Mean Monthly Hours of at Least Moderate Headache Pain Intensity Over Months 1, 2, and 3

Timeframe: Baseline, Month 1, Month 2, and Month 3

NCT IDNCT04252742

SponsorAmgen

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2023-10-26

Results submitted2024-08-06